Why Doesn’t Primary Biliary Cholangitis Respond to Immunosuppressive Medications?

PURPOSE OF REVIEW: The purpose of this review is to discuss reasons why immunosuppressive therapy so far failed in Primary Biliry Cholangitis. RECENT FINDINGS: Even targeted immunosuppressive therapy seems ineffective or potentially harmful. SUMMARY: Bile acid-mediated cholangiocyte damage, facilita...

Descripción completa

Detalles Bibliográficos
Autores principales: Molinaro, Antonio, Marschall, Hanns-Ulrich
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2017
Materias:
Autoimmune, Cholestatic, and Biliary Diseases (S Gordon and C Bowlus, Section Editors)
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5486599/
https://www.ncbi.nlm.nih.gov/pubmed/28706773
http://dx.doi.org/10.1007/s11901-017-0345-y
Descripción
Sumario:PURPOSE OF REVIEW: The purpose of this review is to discuss reasons why immunosuppressive therapy so far failed in Primary Biliry Cholangitis. RECENT FINDINGS: Even targeted immunosuppressive therapy seems ineffective or potentially harmful. SUMMARY: Bile acid-mediated cholangiocyte damage, facilitated by insufficient bicarbonate secretion, seems to attenuate the anti-inflammatory and anti-fibrotic actions of immunosuppressant and immunomodulatory drugs in a clinically significant way.

Ejemplares similares